Effectiveness and Cost of Replacing a Calcineurin Inhibitor With Sirolimus to Slow the Course of Chronic Kidney Disease in Renal Allografts

Transplantation Proceedings

Volumn 42, Issue 1, 2010, Pages 284-287

  Gonzalez F ^b   Espinoza, M ^a   Reynolds, E ^a   Herrera, P ^a   Espinoza, O ^a   Rocca, X ^a   Lorca, E ^b   Hidalgo, J ^a   Roessler, E ^b  

^a UNIVERSITY OF CHILE   (Chile)

^b UNIVERSITY OF CHILE   (Chile)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIHYPERTENSIVE AGENT; ANTILIPEMIC AGENT; AZATHIOPRINE; CALCINEURIN INHIBITOR; CHOLESTEROL; CYCLOSPORIN; CYCLOSPORIN A; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENALAPRIL; EZETIMIBE PLUS SIMVASTATIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; KETOCONAZOLE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; RAPAMYCIN; STEROID; TACROLIMUS; TRIACYLGLYCEROL;

ARTICLE; ATROPHY; CHOLESTEROL BLOOD LEVEL; CHRONIC GRAFT REJECTION; CHRONIC KIDNEY DISEASE; CLINICAL ARTICLE; CLINICAL TRIAL; COST EFFECTIVENESS ANALYSIS; DIASTOLIC BLOOD PRESSURE; DISEASE COURSE; DRUG COST; DRUG SUBSTITUTION; DRUG WITHDRAWAL; FIBROSING ALVEOLITIS; GLOMERULUS FILTRATION RATE; HEALTH CARE COST; HEMATOCRIT; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY ALLOGRAFT; KIDNEY BIOPSY; KIDNEY GRAFT REJECTION; KIDNEY TUBULE; NEPHROTOXICITY; OPEN STUDY; PRIORITY JOURNAL; PROSPECTIVE STUDY; SYSTOLIC BLOOD PRESSURE; TRIACYLGLYCEROL BLOOD LEVEL;

ANTIHYPERTENSIVE AGENTS; AZATHIOPRINE; BLOOD PRESSURE; CHILE; CHOLESTEROL; COST-BENEFIT ANALYSIS; COSTS AND COST ANALYSIS; CYCLOSPORINE; GLOMERULAR FILTRATION RATE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; KETOCONAZOLE; KIDNEY FAILURE; KIDNEY TRANSPLANTATION; MYCOPHENOLIC ACID; PROTEINURIA; SIROLIMUS; TRIGLYCERIDES;

EID: 76749148498     PISSN: 00411345     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.transproceed.2009.12.049     Document Type: Article

References (8)

1. Wolfe R.A., Sabih V.B., Milford E.L., et al. Comparison of mortality in all patients on dialysis, patients on dialysis awaiting transplantation, and recipients of a first cadaveric transplant. N Engl J Med 341 (1999) 1725
2. Marcén R., Pascual J., Teruel J.L., et al. Outcome of cadaveric renal transplant patients treated for 10 years with cyclosporine: is chronic allograft nephropathy the major cause of late graft loss?. Transplantation 72 (2001) 57
3. Nankivell B.J., and Chapman J.R. Chronic allograft nephropathy: current concepts and future directions. Transplantation 81 (2006) 643
4. Brenner B.M., Cooper M.E., de Zeeuw D., et al. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med 345 (2001) 861
5. Webster A., Lee V., Chapman J., et al. Target of rapamycin inhibitors (sirolimus and everolimus) for primary immunosuppression of kidney transplant recipients: a systematic review and meta-analysis of randomized trials. Transplantation 81 (2006) 1234
6. Diekmann F., and Campistol J. Conversion from calcineurin inhibitors to sirolimus in chronic allograft nephropathy: benefits and risks. Nephrol Dial Transplant 21 (2006) 562
7. Ekberg H., Tedesco-Silva H., Demirbas A., et al., ELITE-Symphony Study. Reduced exposure to calcineurin inhibitors in renal transplantation. N Engl J Med 357 (2007) 2562
8. González F., Fuentes V., Castro C., et al. Economic impact of Losartan use in type 2 diabetic patients with nephropathy. Rev Méd Chile 137 (2009) 634